Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk'

Bristol-Myers SquibbThe Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke. People with AFib are five times more likely to have a stroke than those who do not have the condition, and these strokes are more severe and more likely to be fatal than strokes not associated with AFib. Through music, the program aims to inspire people living with AFib, the most common type of irregular heartbeat, to work with their doctor to help reduce their risk of stroke.

Afternoon host of New York’s Classic Rock Station Q104.3 Ken Dashow knows how important it is for people to ‘tune in' to AFib. "When one of my closest friends told me he had AFib and explained the associated increased stroke risk, I had to find a way to use my voice and get involved," said Dashow. "In my more than 30 years of experience in the music industry, I've learned that music has a powerful ability to inspire action. Through 'Tune in to AFib,' we're urging people with AFib to take action by talking to their doctor about how to reduce their stroke risk."

'Tune in to AFib' includes an educational website, TuneintoAFib.com, where people can view exclusive concert footage of Southside Johnny and the Asbury Jukes, hear from Ken Dashow and learn more about AFib and its associated increased stroke risk. The program also encourages people to take an online quiz to determine how 'in tune' they are with AFib and stroke risk. Those who complete the quiz can access an additional exclusive music video and the Bristol-Myers Squibb and Pfizer Alliance will make a $1 donation to the National Stroke Association for each person who completes the quiz, up to $30,000.

With AFib, the top chambers of the heart ("the atria") do not contract properly to push blood through the heart. As a result, some blood remains in the top chambers, which can pool, and clots may form. These clots can travel to the brain, blocking or limiting blood flow, and may result in a stroke.

"Many people with AFib not caused by a heart valve problem don’t have any symptoms and are unaware that the condition is the cause of approximately 15 percent of all strokes," said David Frankel, M.D., Director of the Cardiac Electrophysiology Fellowship Program and Assistant Professor of Medicine at Penn Medicine. "'Tune in to AFib' encourages these people to increase their knowledge of this serious medical condition, recognize their increased stroke risk and work with their doctor to help reduce this risk."

To learn more, visit TuneintoAFib.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Pfizer Inc.: Working together for a healthier world ®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]